

### COPHy 2024 Preliminary Program Updated December 18, 2023

FRIDAY, MAI	RCH 15, 2024
07:30-08:30	Industry Sponsored Breakfast Symposium  HALL A
	(Light breakfast will be served from 07:00-07:30 at the entrance of the hall)
08:30-10:00	BIG CONTROVERSIES IN RETINA IN 2024 HALL A
Chairs:	Baruch Kuppermann, USA; Anat Loewenstein, Israel; Stratos Gotzaridis, Greece; George Charonis, Greece
08:30-08:40	Welcome Remarks Baruch Kuppermann, USA; Anat Loewenstein, Israel; Stratos Gotzaridis, Greece
08:40-09:00	Keynote Lecture:
08:40-08:55	How good are we really without Artificial Intelligence (AI) tools
	<u>Ursula Schmidt-Erfurth</u> , Austria
08:55-09:00	Q&A
09:00-09:30	Debate 1: Is Al ready to replace physicians?
09:00-09:10	Yes: Guiseppe Querques, Italy
09:10-09:20	No: Paolo Lanzetta, Italy
09:20-09:30	Discussion
09:30-10:00	Debate 2: Intraocular inflammation is a major risk factor which should impede us from using anti complement agents for Geographic atrophy
09:30-09:40	Yes: <u>Dinah Zur</u> , Israel
09:40-09:50	No: Jordi Monés, Spain
09:50-10:00	Discussion
10:00-10:30	Visit Exhibition, Posters & Coffee and Refreshment Break



DAY, MARCH	15, 2024		
	HALL A		HALL B
10:30-12:00 MI	EDICAL RETINA 1   Neovascular ("Wet") AMD Management	10:30-12:00	GLAUCOMA 1
Chairs: Ba	aruch Kuppermann, USA	Chairs:	Francesca Cordeiro, UK; George Mangouritsas, Gree
	ebate 1: New generation molecules as first-line treatment in eovascular AMD	10:30-11:00	Debate 1: SLT – first-line or second-line?
10:30-10:40 Ye	es: Patricia Udaondo, Spain	10:30-10:40	Yes: Dimitrios Besinis, Greece
10:40-10:50 No	o: Reinier Schlingemann, Netherlands	10:40-10:50	No: Ioannis Halkiadakis, Greece
10:50-11:00 Dis	iscussion	10:50-11:00	Discussion
	ebate 2: We are already in the era of personalized treatment	11:00-11:30	Debate 2: IOP assessment – Are Diurnal measureme than alternatives e.g. Water Drinking Test?
11:00-11:10 Ye	es: <b>Stela Vujosevic</b> , Italy	11:00-11:10	Yes: John Danias, USA
11:10-11:20 No	o: Francesco Bandello, Italy	11:10-11:20	No: Ioannis Halkiadakis, Greece
11:20-11:30 Dis	iscussion	11:20-11:30	Discussion
	ebate 3: Durability associated with multi target therapies is uperior to anti-VEGF mono-target therapy in AMD	11:30-12:00	Debate 3: NTG – Is this a separate disease from POA
11:30-11:40 Ye	es: Irini Chatziralli, Greece	11:30-11:40	Yes: John Danias, USA
11:40-11:50 No	o: Reinier Schlingemann, Netherlands	11:40-11:50	No: Francesca Cordeiro, UK
11:50-12:00 Dis	iscussion	11:50-12:00	Discussion
	dustry Sponsored Luncheon Symposium unch boxes served 12:00-12:15)		HA
	dustry-Sponsored Dessert Symposium Dessert boxes served 13:15-13:30)		HA
14:30-15:00 Vis	sit Exhibition, Posters & Coffee and Refreshment Break		EXHIBITION A



FRIDAY, MAR	RCH 15, 2024		
	HALL A		HALL B
15:00-16:30	SURGICAL RETINA 1   Controversial Approaches to Common Surgical Questions	15:00-16:30	GLAUCOMA 2
Chairs:	William F. Mieler, USA; Stanislao Rizzo, Italy, Stratos Gotzaridis, Greece	Chairs:	Francesca Cordeiro, UK; Petros Smahliou, Greece
15:00-15:30	Debate 1: Vitrectomy is safe and effective in the management of visually significant floaters (myodesopsia)	15:00-15:30	Debate 1: MIGS - first-line or second-line?
15:00-15:10	Yes: Petros Petrou, Greece	15:00-15:10	Yes: Ioanna Tryfinopoulou, Greece
15:10-15:20	No: William F. Mieler, USA	15:10-15:20	No: Dimitrios Besinis, Greece
15:20-15:30	Discussion	15:20-15:30	Discussion
15:30-16:00	Debate 2: In epiretinal membrane (ERM) surgery, removal of the internal limiting membrane (ILM) is essential to improve vision and limit recurrences	15:30-16:00	Debate 2: MIGS – Should all devices have corneal endocell counts?
15:30-15:40	Yes: Francesco Boscia, Italy	15:30-15:40	Yes: Stelios Kandarakis, Greece
15:40-15:50	No: William F. Mieler, USA	15:40-15:50	No: George Mangouritsas, Greece
15:50-16:00	Discussion	15:50-16:00	Discussion
16:00-16:30	Debate 3: Treatment of recurrent macular hole should include the use of a free ILM flap or other intraoperative surgical adjuvants	16:00-16:30	Debate 3: Neuroprotection – can we really measure it in glaucoma?
16:00-16:10	Yes: Orit Vidne, Israel	16:00-16:10	Yes: Francesca Cordeiro, UK
16:10-16:20	No: Stanislao Rizzo, Italy	16:10-16:20	No: George Mangouritsas, Greece
16:20-16:30	Discussion	16:20-16:30	Discussion



6:30-17:30		HALLA
	VISION ACADEMY IN RETINA 2024   Artificial intelligence in retinal disease management: evolution or revolution?	HALL A
Chairs:	Anat Loewenstein, Israel Baruch Kuppermann, USA	
6:30-16:35	Introduction to the Vision Academy	
	Anat Loewenstein, Israel	
6:35-16:45	Al in retinal disease screening and diagnosis – introduction to current and future options	
	Paolo Lanzetta, Italy	
6:45-16:55	Al in retinal disease management –introduction to current and future options	
	Tariq Aslam, UK	
6:55-17:00	Q&A	
	Moderated by: Baruch Kuppermann, USA	
7:00-17:30	Panel discussion / Audience Q&A	
	Considerations for implementing AI solutions in clinical practice – impact on patients and HCPs	
	Moderators: Anat Loewenstein, Israel; Baruch Kuppermann, USA	
	Panelists: Dinah Zur, Israel	
	Paolo Lanzetta, Italy	
	Tariq Aslam, UK	
	Javier Zarranz-Ventura, Spain	
	Session Close:	
	Anat Loewenstein, Israel; Baruch Kuppermann, USA	
7:30-18:30	Industry Sponsored Symposium	HALL A
8:30-19:30	"Happy Hour" Cocktail	<b>EXHIBITION AREA</b>



HALL A  LL RETINA 2   Diabetic Macular Edema (DME) and ative Diabetic Retinopathy  co Bandello, Italy; Irini Chatziralli, Greece  1: Oral drugs have the potential to be beneficial for the progression of NPDR i Chatziralli, Greece  in Zur, Israel  on  2: Are regular anti-VEGF injections beneficial for long	08:30-10:00  Chairs: 08:30-09:00  08:30-08:40 08:40-08:50 08:50-09:00	HALL B  NEURO-OPHTHALMOLOGY 1   The Afferent Pathway  Andrew G. Lee, USA  Debate 1: Should all elderly patients with acute visual loss go to the ER for stroke evaluation and treatment?  Yes: John Chen, USA  No: Susan Mollan, UK  Discussion
tive Diabetic Retinopathy  co Bandello, Italy; Irini Chatziralli, Greece  1: Oral drugs have the potential to be beneficial for the progression of NPDR  i Chatziralli, Greece th Zur, Israel on	Chairs: 08:30-09:00 08:30-08:40 08:40-08:50 08:50-09:00	Andrew G. Lee, USA  Debate 1: Should all elderly patients with acute visual loss go to the ER for stroke evaluation and treatment?  Yes: John Chen, USA  No: Susan Mollan, UK  Discussion
I: Oral drugs have the potential to be beneficial for he progression of NPDR i Chatziralli, Greece th Zur, Israel on	08:30-09:00 08:30-08:40 08:40-08:50 08:50-09:00	Debate 1: Should all elderly patients with acute visual loss go to the ER for stroke evaluation and treatment?  Yes: John Chen, USA  No: Susan Mollan, UK  Discussion
he progression of NPDR i Chatziralli, Greece th Zur, Israel on	08:30-08:40 08:40-08:50 08:50-09:00	the ER for stroke evaluation and treatment? Yes: John Chen, USA No: Susan Mollan, UK Discussion
nh Zur, Israel on	08:40-08:50 08:50-09:00	No: <u>Susan Mollan</u> , UK Discussion
on	08:50-09:00	Discussion
2: Are regular anti-VEGF injections beneficial for long	09-00-09-30	Dahata 2. Dationto with viewal analy avadrance about duradown
nagement of diabetic retinopathy?	03.00 03.00	Debate 2: Patients with visual snow syndrome should undergo work up and treatment?
ncesco Bandello, Italy	09:00-09:10	Yes: Eleni Papageorgiou, Greece
naella Goldstein, Israel	09:10-09:20	No: Andrew G. Lee, USA
on	09:20-09:30	Discussion
3: Is high dose anti-VEGF monotherapy superior to dose anti-VEGF monotherapy for DME	09:30-10:00	Case Presentations  Moderator. John Chen, USA
at Loewenstein, Israel		Panelists: All Speakers
naella Goldstein, Israel		
on		
	dose anti-VEGF monotherapy for DME at Loewenstein, Israel naella Goldstein, Israel	dose anti-VEGF monotherapy for DME  at Loewenstein, Israel  naella Goldstein, Israel



SATURDAY, I	MARCH 16, 2024		
	HALL A		HALL B
10:30-12:00	MEDICAL RETINA 3   AMD and Hereditary Retinal Degeneration Topics	10:30-12:00	UVEITIS 1
Chairs:	<u>Tryfon Rotsos</u> , Greece	Chairs:	Bahram Bodaghi, France; Zohar Habot-Wilner, Israel
10:30-11:00	Debate 1: Complement inhibition is generally recommended for patients with geographic atrophy	10:30-11:00	Debate 1: Multifocal lenses in uveitic cataract
10:30-10:40	Yes: Ursula Schmidt-Erfurth, Austria	10:30-10:40	Yes: Aniruddha Agarwal, UAE
10:40-10:50	No: TBA	10:40-10:50	No: Bahram Bodaghi, France
10:50-11:00	Discussion	10:50-11:00	Discussion
11:00-11:30	Debate 2: Gene therapy is the new era of treating retinal diseases	11:00-11:30	Debate 2: The use of biosimilar drugs in uveitis
11:00-11:10	Yes: Hendrik Scholl, Switzerland	11:00-11:10	Yes: Sarah Touhami, France
11:10-11:20	No: Patricia Udaondo, Spain	11:10-11:20	No: Sofia Androudi, Greece
11:20-11:30	Discussion	11:20-11:30	Discussion
11:30-12:00	Debate 3: Biosimilars are equivalent to established Anti-VEGF agents to treat neovascular AMD	11:30-12:00	Debate 3: OCT-Angiography is a Must-Have Tool for the Management of White Dot Syndromes
11:30-11:40	Yes: Baruch Kuppermann, USA	11:30-11:40	Yes: Bahram Bodaghi, France
11:40-11:50	No: <u>Javier Zarranz-Ventura</u> , Spain	11:40-11:50	No: Zohar Habot-Wilner, Israel
11:50-12:00	Discussion		
12:15-13:15	Industry-Sponsored Luncheon Symposium (Lunch boxes served 12:00-12:15)		HALL A
13:30-14:30	Industry-Sponsored Dessert Symposium (Dessert boxes served 13:15-13:30)		HALL A
14:30-15:00	Visit Exhibition, Posters & Coffee and Refreshment Break		EXHIBITION AREA



	MARCH 16, 2024		
	HALL A		HALL B
15:00-16:30	SURGICAL RETINA 2   Controversies in the Utilization of Cutting Edge Vitreoretinal Surgical Technology	15:00-16:30	NEURO-OPHTHALMOLOGY 2   The Efferent Pathway
Chairs:	<u>Stratis Paroikakis</u> , Greece, <u>Jose Maria Ruiz-Moreno</u> , Spain, <u>William F. Mieler</u> , USA	Chairs:	Andrew G. Lee, USA
15:00-15:30	Debate 1: The use of the heads up, digital imaging operating microscope, has led to significant visual and anatomic improvement in surgical outcomes	15:00-15:30	Debate 1: Should all patients with myasthenia gravis be offered thymectomy?
15:00-15:10	Yes: Stratos Gotzaridis, Greece	15:00-15:10	Yes: John Chen, USA
15:10-15:20	No: William F. Mieler, USA	15:10-15:20	No: Eleni Papageorgiou, Greece
15:20-15:30	Discussion	15:20-15:30	Discussion
15:30-16:00	Debate 2: Surgical intraoperative OCT is essential for best anatomic outcomes in macular surgery	15:30-16:00	Debate 2: Should all patients with idiopathic intracranial hypertension (IIH) have an LP?
15:30-15:40	Yes: Efstratis Paroikakis, Greece	15:30-15:40	Yes: Susan Mollan, UK
15:40-15:50	No: Jose Maria Ruiz-Moreno, Spain	15:40-15:50	No: Andrew G. Lee, USA
15:50-16:00	Discussion	15:50-16:00	Discussion
16:00-16:30	Debate 3: The use of intravitreal methotrexate in the management of RD with significant PVR leads to better anatomic and visual outcomes	16:00-16:30	Case Presentations Moderator: John Chen, USA
16:00-16:10	Yes: Theodoros Giannopoulos, Greece		Panelists: All Speakers
16:10-16:20	No: Francesco Boscia, Italy		
16:20-16:30	Discussion		



SATURDAY, I	MARCH 16, 2024		
	HALL A		HALL B
16:30-18:00	MEDICAL RETINA 4   New Treatment Strategies	16:30-18:00	UVEITIS 2
Chairs:	Baruch Kuppermann, USA; Ursula Schmidt-Erfurth, Austria	Chairs:	Bahram Bodaghi, France; Zohar Habot-Wilner, Israel
16:30-17:00	Debate 1: The role of biosimilars will remain important even with many new non-biosimilar drug options becoming available	16:30-17:00	Debate 1: Prophylactic laser photocoagulation and vitrectomy for ARN
16:30-16:40	Yes: Stela Vujosevic, Italy	16:30-16:40	Yes: Marilita Moschos, Greece
16:40-16:50	No: <b>Sobha Sivaprasad</b> , UK	16:40-16:50	No: Sarah Touhami, France
16:50-17:00	Discussion	16:50-17:00	Discussion
17:00-17:30	Debate 2: Genetic treatment has the potential to change the outcome of AMD patients	17:00-17:30	Debate 2: Topical prostaglandins can be given in eyes with uveitis
17:00-17:10	Yes: Hendrik Scholl, Switzerland	17:00-17:10	Yes: Zohar Habot-Wilner, Israel
17:10-17:20	No: <b>Sobha Sivaprasad</b> , UK	17:10-17:20	No: Sofia Androudi, Greece
17:20-17:30	Discussion	17:20-17:30	Discussion
17:30-18:00	Debate 3: Are OCT parameters better than visual acuity in determining the benefit of new dry AMD agents?	17:30-18:00	Debate 3: Glaucoma tube shunts are better than trabeculectomy for uveitic glaucoma
17:30-17:40	Yes: TBA	17:30-17:40	Yes: Marilita Moschos, Greece
17:40-17:50	No: <u>Jordi Monés</u> , Spain	17:40-17:50	No: Aniruddha Agarwal, UAE
17:50-18:00	Discussion	17:50-18:00	Discussion
	End of Congress		End of Congress